Sellas, Life

Sellas Life Sciences: Three Readouts, One Yardstick for SLS009 and REGAL

Published on 11/16/2026 at 07:01 | Editorial boerse-global.de
Sellas posted a $10.1M Q3 net loss and $134.7M in cash, with REGAL Phase 3 topline due by end-November and SLS009 Phase 2 data set for ASH.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences closed the third quarter of 2026 with a net loss of $10.1 million, or $0.05 per share, and reported cash and cash equivalents of $134.7 million as of September 30, 2026. The figures, filed with the SEC on Form 8-K on Thursday, frame a company whose near-term story is told almost entirely in clinical milestones rather than in earnings.

That calendar is unusually crowded — and unusually easy to misread. Three separate disclosures are queued up, each answering a different question about a different patient population.

The November Readout That Actually Matters

The centerpiece is REGAL, the company's Phase 3 study. Sellas reiterated on Thursday that it expects topline results on the trial's primary endpoint before November is out. An anticipated release date, though, is not a study result; the date only fixes when the question gets answered, not what the answer will be.

ASH Brings Phase 2 Data — With a Specific Treatment History

Separately, Sellas said on November 4 that it will present completed Phase 2 data on SLS009 at the ASH annual meeting, scheduled for December 12–15, 2026, with the presentation itself set for December 14. The data cover patients with relapsed or refractory AML and were generated in combination with azacitidine and venetoclax, following prior treatment on a venetoclax-based regimen.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

That treatment sequence is no footnote. It defines the setting in which the results were produced, and it belongs alongside the headline efficacy figures rather than behind them.

In relapsed or refractory monocytic AML at the selected dose, Sellas reported an overall response rate of 54% and a median overall survival of 5.8 months. For AML carrying a TP53 mutation, the response rate came in at 57%, with median overall survival of 8.8 months.

Response and survival sit side by side here, and they should be read that way. A response rate on its own does not capture the full clinical picture the company has disclosed; equally, the survival figure cannot be detached from the patient group it describes. Nor do the two cohorts form a simple ranking — Sellas has reported outcomes for distinctly defined populations, and that labeling is part of what the data say.

A Second, Separate Dataset Is Coming

Also on the docket: preliminary data from a Phase 2 study of SLS009 in newly diagnosed AML, expected in the fourth quarter of 2026. This is a different treatment setting from the ASH presentation, and the two should not be folded into a single success narrative simply because they share a drug name. The same molecule does not make different studies interchangeable.

A Passive Stake, Not a Fresh Purchase

On the ownership side, State Street Corporation disclosed a 5.1% holding in Sellas on November 10 via a Schedule 13G filing. The disclosure names September 30, 2026 as the relevant position date and does not document a newly reported purchase of shares.

Sellas Life Sciences at a turning point? This analysis reveals what investors need to know now.

What the Sequence Demands

Taken together, the three catalysts pose a straightforward test for investors: how much conviction can an encouraging intermediate step support? Only as much as the specific study behind it can bear. The ASH presentation may deepen the SLS009 discussion, but it substitutes for neither the newly diagnosed AML data nor the pending REGAL result. The proximity of these announcements argues for keeping them rigorously separate rather than bundling them into one story.

The measure to watch is not the number of positive-sounding phrases in a press release. It is whether each successive disclosure meets the clinical expectation attached to it — and at Sellas, that means tracking the calendar closely while keeping the studies firmly apart.

Ad

Sellas Life Sciences Stock: New Analysis - 16 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70519360 |